Category Archives: Uncategorized

25 Jan

Solid Delays IPO, Discloses Duchenne Problems & Raises Rivals’ Hackles

Solid Biosciences was expected to ride gene therapy’s wave of recent momentum to an IPO this week. But the offering,

25 Jan

BUILDING A LOW-CARBON, CLIMATE RESILIENT FUTURE: SECURE, CLEAN AND EFFICIENT ENERGY

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: H2020-LC-SC3-2018-2019-2020Pillar: Societal ChallengesPlanned Opening Date: Deadline: Thu, 30 Apr 2020 17:00:00 (Brussels local time)Modification Date: Thu, 25

24 Jan

The Value of Academic-Industry Partnerships

More than a decade ago, the NIH Roadmap and the FDA Critical Path Report brought significant public attention and new programmatic efforts

24 Jan

Research Headlines – Photocatalytic wastewater treatment in a new light

[Source: Research & Innovation] Olive oil, palm oil, seafood – for small producers of such goods, for example in rural

24 Jan

Boston Scientific Pumps $90M Into Heart Device Startup Millipede

Boston Scientific is infusing medical device company Millipede with $90 million, an equity investment that comes with the option to

23 Jan

NeuroPointDX Turns to Crowdfunding to Get Key Study Past Finish Line

Autism is hard to diagnose-there’s currently no medical test to diagnose the disorder, and teams of experts typically make diagnosis

23 Jan

Research Headlines – Refining medical research methods for better results

[Source: Research & Innovation] Billions of euros are wasted ever year on research that is redundant, flawed, never published or

23 Jan

Combating Antimicrobial Resistance

Here’s a statistic you might not have known: an estimated 700,000 people die each year due to the growing number

22 Jan

4 Things Millennials Should Know (and Love!) About Food and Farming

One of the things that we at GMO Answers emphasize is finding common ground. In this time of polarization, with

22 Jan

BioCryst, Idera Plan Merger in Tie-Up of Rare Disease Drug Developers

BioCryst Pharmaceuticals and Idera Pharmaceuticals have struck a deal to combine into a single company focused on treatments for rare